These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22698418)

  • 1. Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms.
    Lee KS; Lee YS; Kim JC; Seo JT; Lee JZ; Choo MS
    Int J Clin Pract; 2012 Jul; 66(7):663-70. PubMed ID: 22698418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument.
    Zinner N; Kobashi K; Koochaki P; Fix D; Egermark M
    Neurourol Urodyn; 2011 Jan; 30(1):62-8. PubMed ID: 20860020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms.
    Brubaker L; Piault EC; Tully SE; Evans CJ; Bavendam T; Beach J; Yeh Y; Kopp ZS; Khullar V; Kelleher CJ; Trocio J
    Int J Clin Pract; 2013 Apr; 67(4):342-50. PubMed ID: 23521326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
    Kaplan SA; Goldfischer ER; Steers WD; Gittelman M; Andoh M; Forero-Schwanhaeuser S
    Aging Male; 2010 Jun; 13(2):100-7. PubMed ID: 20001469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.
    Yoo DS; Han JY; Lee KS; Choo MS
    Int J Clin Pract; 2012 Feb; 66(2):132-8. PubMed ID: 22188444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.
    Michel MC; Oelke M; Goepel M; Beck E; Burkart M
    Neurourol Urodyn; 2007; 26(2):190-5. PubMed ID: 17096320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 May; 107(10):1612-7. PubMed ID: 21070569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study.
    Gollar KM; Young DG; Bailen J; He W; Forero-Schwanhaeuser S
    Urol Nurs; 2012; 32(1):38-46, 50. PubMed ID: 22474864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.